Grant Pickering - 27 Jul 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: PCVX
Reported as of: 27 Jul 2026
Net transaction value: -$1,012,375
SEC form: 4
Accepted by SEC: 28 Jul 2026, 16:10:39 UTC
Prior SEC filing: 26 Jun 2026
Source filing: View source filing
Reporting owner signature: Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact

Key filing fact

Grant Pickering filed Form 4 for Vaxcyte, Inc. (PCVX) on 28 Jul 2026.

Key facts

This page summarizes Grant Pickering's Form 4 filing for Vaxcyte, Inc. (PCVX).
8 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 Jul 2026, 16:10.

Change

Previous filing in this sequence was filed on 26 Jun 2026.
Current net transaction value: -$1,012,375.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001258693 Primary reporting owner

PICKERING GRANT

Relationship: CHIEF EXECUTIVE OFFICER, Director
Address: C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS
Signature: Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact
Signature date: 28 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCVX transaction

Common Stock

Options Exercise

Transaction value
Shares: +16,198
Change %: +3.6%
Price: $2.03^*
Shares after: 469,445
Date: 27 Jul 2026
Ownership: Direct
Footnotes: F1

PCVX transaction

Common Stock

Sale

Transaction value: $654,133
Shares: -11,783
Change %: -2.5%
Price: $55.52
Shares after: 457,662
Date: 27 Jul 2026
Ownership: Direct
Footnotes: F2, F3

PCVX transaction

Common Stock

Sale

Transaction value: $246,935
Shares: -4,415
Change %: -0.96%
Price: $55.93
Shares after: 453,247
Date: 27 Jul 2026
Ownership: Direct
Footnotes: F2, F4

PCVX transaction

Common Stock

Sale

Transaction value: $41,970
Shares: -756
Change %: -0.56%
Price: $55.52
Shares after: 133,459
Date: 27 Jul 2026
Ownership: By Children's Trust
Footnotes: F2, F5, F6

PCVX transaction

Common Stock

Sale

Transaction value: $13,655
Shares: -244
Change %: -0.18%
Price: $55.96
Shares after: 133,215
Date: 27 Jul 2026
Ownership: By Children's Trust
Footnotes: F2, F6, F7

PCVX transaction

Common Stock

Sale

Transaction value: $34,546
Shares: -622
Change %: -0.46%
Price: $55.54
Shares after: 133,593
Date: 27 Jul 2026
Ownership: By Children's Trust
Footnotes: F2, F5, F8

PCVX transaction

Common Stock

Sale

Transaction value: $21,135
Shares: -378
Change %: -0.28%
Price: $55.91
Shares after: 133,215
Date: 27 Jul 2026
Ownership: By Children's Trust
Footnotes: F2, F8, F9

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -16,198
Change %: -11%
Price: $0.000000^*
Shares after: 137,000
Date: 27 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,198
Exercise price: $2.03
Footnotes: F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 10 footnotes

Footnote F1

Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.

Footnote F2

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

Footnote F3

The price reported is a weighted-average price. The shares were sold at prices ranging from $54.77 to $55.765. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F4

The price reported is a weighted-average price. The shares were sold at prices ranging from $55.77 to $56.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F5

The price reported is a weighted-average price. The shares were sold at prices ranging from $54.77 to $55.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F6

Shares are held directly by a trust for the benefit of the Reporting Person's son.

Footnote F7

The price reported is a weighted-average price. The shares were sold at prices ranging from $55.81 to $56.18. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F8

Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

Footnote F9

The price reported is a weighted-average price. The shares were sold at prices ranging from $55.82 to $56.085. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F10

Option is fully vested and exercisable.